Courtagen Inks Emerging Markets Deal with Alliance Global Group | GenomeWeb
Home » Courtagen Inks Emerging Markets Deal with Alliance Global Group

Courtagen Inks Emerging Markets Deal with Alliance Global Group

Nov 15, 2012
|
a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said that Alliance Global Group will distribute the firm's molecular diagnostic tests in certain emerging markets.

Dubai-based Alliance Global sells biomedical products in the Middle East, Africa, and Asia. It will have exclusive rights to distribute a number of Courtagen tests for genetically based disorders. Thus far, the Woburn, Mass.-based firm offers tests for mitochondrial disorders and a new panel for epilepsy and seizure. Courtagen also plans to develop tests for other neurological disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Jan 21, 2016

Courtagen Receives Clinical Laboratory Approval in New York State

Sep 16, 2016

Courtagen, Astellas Partner on Mitochondrial Disease Drug Development

Jan 21, 2016

Clinical Exomes Reveal Multiple Molecular Diagnoses With Surprising Frequency, Baylor Team Finds

Premium
Jul 19, 2016

Clinical Genomics Approach Offers Increased Diagnostic Yield for Intellectual Disability

Jul 15, 2016

Ethics, Guidelines for Molecular Autopsy in Youth Sudden Death Explored by Texas Team

Feb 19, 2016

In Brief This Week: Ambry Genetics; ArcherDX; EpiCypher; and More

The Scan

This Week in PLOS

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Even More Data to Mine

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

New Spaces in Connecticut

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Healthier, If Not Longer, Life

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.

What's Popular?

In Clinical Sequencing

  1. Investigators Weigh Nitty Gritty of Sequencing Costs, Question $1,000 Genome

    Premium

  2. FDA Engages Lab, Dx Players by Proposing NGS Regulatory Standards Come From Community

    Premium

  3. UK Team Demonstrates MinIon for UTI Dx, Plans to Develop Sepsis and Respiratory Infection Tests

    Premium

  4. Researchers Hope PharmCAT Tool Will Help Improve Clinical Implementation of Pharmacogenomics

    Premium

  5. Personal Genome Diagnostics Looking to Develop IVD Assays With Pharma Partners

    Premium

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.